Withuspharmaceutical Co.Ltd
WITHUS PHARMACEUTICAL Co.,LTD. engages in the production and sale of pharmaceutical products in South Korea. It offers circulatory agents, endocrine cost medications, osteoporosis treatment products, antithrombotic medicines, central nervous system agents, digestive tract medications, respiratory/skin preparations, musculoskeletal medications, antibiotics, antifungal and antiviral drugs, genitour… Read more
Withuspharmaceutical Co.Ltd (330350) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.002x
Based on the latest financial reports, Withuspharmaceutical Co.Ltd (330350) has a cash flow conversion efficiency ratio of -0.002x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-208.65 Million) by net assets (₩98.22 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Withuspharmaceutical Co.Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Withuspharmaceutical Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Withuspharmaceutical Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Withuspharmaceutical Co.Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hong Ho Precision Textile Co Ltd
TW:1446
|
0.002x |
|
Birikim Varlik Yonetim A.S.
IS:BRKVY
|
-0.079x |
|
Master Tec Group Berhad
KLSE:0295
|
0.100x |
|
Mcleod Russel India Limited
NSE:MCLEODRUSS
|
0.415x |
|
BATI EGE GMYO
IS:BEGYO
|
-0.001x |
|
Mahachai Hospital Public Company Limited
BK:M-CHAI
|
0.074x |
|
LEBON NOM. O.N.
F:88J
|
N/A |
|
Sensys Gatso Group AB
ST:SGG
|
0.184x |
Annual Cash Flow Conversion Efficiency for Withuspharmaceutical Co.Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Withuspharmaceutical Co.Ltd from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩93.12 Billion | ₩9.63 Billion | 0.103x | +854.86% |
| 2023-12-31 | ₩90.28 Billion | ₩-1.24 Billion | -0.014x | -121.15% |
| 2022-12-31 | ₩83.04 Billion | ₩5.38 Billion | 0.065x | -34.65% |
| 2021-12-31 | ₩80.91 Billion | ₩8.02 Billion | 0.099x | +841.48% |
| 2020-12-31 | ₩76.88 Billion | ₩809.54 Million | 0.011x | -89.80% |
| 2019-12-31 | ₩76.76 Billion | ₩7.93 Billion | 0.103x | -19.97% |
| 2018-12-31 | ₩52.43 Billion | ₩6.77 Billion | 0.129x | -14.38% |
| 2017-12-31 | ₩44.10 Billion | ₩6.65 Billion | 0.151x | -- |